Bioporto A/S
CSE:BIOPOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioporto A/S
Operating Income
Bioporto A/S
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Operating Income
-kr86.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-21%
|
|
|
Genmab A/S
CSE:GMAB
|
Operating Income
kr1.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
28%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Income
kr7.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Operating Income
-$16.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Income
-€136.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-13%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Income
kr1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
35%
|
CAGR 10-Years
63%
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Operating Income?
Operating Income
-86.1m
DKK
Based on the financial report for Dec 31, 2025, Bioporto A/S's Operating Income amounts to -86.1m DKK.
What is Bioporto A/S's Operating Income growth rate?
Operating Income CAGR 10Y
-21%
Over the last year, the Operating Income growth was -14%. The average annual Operating Income growth rates for Bioporto A/S have been -3% over the past three years , -6% over the past five years , and -21% over the past ten years .
